U-Blot® Research Grade Toripalimab
Ucallm.jpg
$9,999.00
Product details
Background：Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929
• The diverse functions of the PD1 inhibitory pathway., PMID:28990585
• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007
• Overcoming T cell exhaustion in infection and cancer., PMID:25797516
• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727
• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275
• PD-L1., PMID:29097600
Specifications
| Target | CD1 |
| Reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | Humanized |
| Isotype | IgG4-kappa |
| Conjugate/Modification | |
| Modification | |
| Recommended Dilution Ratio | |
| Composition | 0.01M PBS, pH 7.4. |
| Purification Process | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Storage Condition | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | |
| Immunogen | Mammalian Cells |
| Gene Name | |
| Protein Name | |
| Alias | Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 |
| Species | |
| Gene ID-1 | Q15116 |
| Uniprot | |
| Species.1 | |
| Gene ID | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.1 | |
| Uniprot.2 | |
| Organism-4 | |
| Gene ID-4 | |
| SwissProt-4 | |
| Description | Background：Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. PD-1 is a negative regulator of immune activation that is considered a foundational target within the immuno-oncology market.<br>• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870<br />• PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations., PMID:30888929<br />• The diverse functions of the PD1 inhibitory pathway., PMID:28990585<br />• PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy., PMID:30191996<br />• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845<br />• PD-1 expression and clinical PD-1 blockade in B-cell lymphomas., PMID:29118007<br />• Overcoming T cell exhaustion in infection and cancer., PMID:25797516<br />• Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker., PMID:32875727<br />• Tumor Mutational Burden and Response Rate to PD-1 Inhibition., PMID:29262275<br />• PD-L1., PMID:29097600<br /> |
| Cellular Localization | |
| Tissue Expression | |
| Signaling_pathway | |
| Research Areas | |
| Function |
Please login to post questions
Related products
